New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
Xconomy
AUGUST 26, 2019
Four years after approval the two PCSK9 blockers on the market have yet to crack $1 billion in annual sales, combined, thanks to a gloves-off effort by insurers to beat back their use. Results from a big study are due Sept. One of the two drugs might even be on life support. Now a third PCSK9 inhibitor is in the ring.
Let's personalize your content